All patients
corticosteroids: no corticosteroids: yes critical disease severe disease
Immunosuppressants drugs in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
CAN-COVID, 2020 0.67 [0.30; 1.50]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
0.70 [0.58 ; 0.84 ] ACTT-2 (Kalil), 2020, CAN-COVID, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, NCT04412772 (ARCHITECTS), 0, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 2021 10 2% 4,517 low low death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
CAN-COVID, 2020 0.67 [0.30; 1.50]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
EMPACTA, 2020 1.13 [0.54; 2.40]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
0.75 [0.62 ; 0.89 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, LIVE-AIR (Temesgen), 2021, NCT04412772 (ARCHITECTS), 0, Rosas (REMDACTA), 2021, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 2021 16 13% 6,723 moderate low deaths (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
0.77 [0.59 ; 1.02 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, LIVE-AIR (Temesgen), 2021, Rosas (REMDACTA), 2021 5 51% 4,129 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
EMPACTA, 2020 0.55 [0.33; 0.92]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
0.64 [0.40 ; 1.03 ] BACC Bay Tocilizumab Trial, 2020, COV-BARRIER, 2021, EMPACTA, 2020, SAVE-MORE, 2021, STOP-COVID (Guimarães), 2021 5 74% 1,767 low serious clinical improvementdetailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
CAN-COVID, 2020 1.39 [0.76; 2.54]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
EMPACTA, 2020 1.15 [0.90; 1.47]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.17 [1.08 ; 1.28 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 10 0% 4,057 low low clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
1.31 [1.13 ; 1.52 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022 3 0% 2,659 low not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.33 [0.95 ; 1.87 ] COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 4 0% 564 moderate not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
EMPACTA, 2020 1.15 [0.90; 1.47]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
1.14 [1.03 ; 1.27 ] ACTT-2 (Kalil), 2020, EMPACTA, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 4 0% 1,539 low not evaluable death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
EMPACTA, 2020 0.56 [0.32; 0.97]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
0.73 [0.62 ; 0.87 ] ACTT-2 (Kalil), 2020, BACC Bay Tocilizumab Trial, 2020, EMPACTA, 2020, LIVE-AIR (Temesgen), 2021, Rosas (REMDACTA), 2021, STOP-COVID (Guimarães), 2021 6 6% 2,213 moderate not evaluable hospital dischargedetailed results EMPACTA, 2020 1.16 [0.90; 1.49]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
1.05 [0.88 ; 1.25 ] EMPACTA, 2020, Rosas (REMDACTA), 2021 2 13% 649 moderate not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
0.62 [0.46 ; 0.84 ] ACTT-2 (Kalil), 2020, COVACTA (Rosas), 2020, SAVE-MORE, 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 5 0% 1,925 low serious ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
0.48 [0.25 ; 0.94 ] COVACTA (Rosas), 2020 1 0% 191 NA not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
1.57 [0.77 ; 3.20 ] COV-BARRIER (critically ill), 2022 1 0% 101 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
CAN-COVID, 2020 0.73 [0.45; 1.19]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
0.91 [0.75 ; 1.11 ] BACC Bay Tocilizumab Trial, 2020, CAN-COVID, 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021 6 0% 2,272 moderate serious superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] ACTT-2 (Kalil), 2020 1 0% 1,033 NA not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
1.09 [0.81 ; 1.46 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 6 24% 1,607 moderate serious 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 18:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526
- roots T: 290
